PCC Rokita SA (PCR) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of PCC Rokita SA PLN 83.92, price PLN 67.00, upside +25.3%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PCC Rokita SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 44.32 PLN – 103.62 PLN · fair‑value band 64.57 PLN – 104.91 PLN · the 67.00 PLN price screens below the 83.92 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow PCC Rokita in your weekly email
Every Wednesday you see whether PCC Rokita is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PCC Rokita SA designs, produces, and sells chemical products in Poland, Germany, the European Union, rest of Europe, the United States, Asia, and internationally. It operates through five segments: Polyurethanes, Chlorine Derivatives, Other Chemical Activities, Energy, and Other Activities.
Show more
PCC Rokita SA designs, produces, and sells chemical products in Poland, Germany, the European Union, rest of Europe, the United States, Asia, and internationally. It operates through five segments: Polyurethanes, Chlorine Derivatives, Other Chemical Activities, Energy, and Other Activities. The Polyurethanes segment produces polyols, polyurethane systems, and prepolymers; and flexible foams, rigid foams, coatings, elastomers, adhesives, impregnations, and other products. The Chlorine Derivatives segment provides chlorine, sodium hydroxide, caustic soda, chlorobenzene, and hydrochloric acid. The Other Chemical Activities segment offers phosphorus-derivative and naphthalene-derivative products. The Energy segment produces and distributes electricity, thermal energy, demineralized water, and compressed air. The Other Operations segment is involved in the provision of maintenance services for technological equipment and installations; industrial waste management; hazardous goods transport services; management and administration services; environmental protection; asset management and security; construction and repairs of steel industrial equipment; and trades in chemical products, and other. It also provides transport and freight, and maintenance services; research of chemical substances; and designs, constructs, and assembles, as well as repairs industrial equipment, tanks, pipelines, and welded structure. The company sells its products under the Crossin, Ekoprodur, ROKOPOL, and ROKESTER brands. PCC Rokita SA was incorporated in 2002 and is headquartered in Brzeg Dolny, Poland. PCC Rokita SA is a subsidiary of PCC SE.
Stock analysis
PCC Rokita SA (PCR) currently trades at 67.00 PLN, while our model-based Fair Value estimate is 83.92 PLN, implying the stock looks roughly 20.2% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 64.39 PLN per share, and 6 of the 24 models we run sit above the 67.00 PLN price.
Bear case: the Earnings-Based group reads lowest at 25.93 PLN, and 18 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 64.57 PLN (bear) to 104.91 PLN (bull), the price of 67.00 PLN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
PCC Rokita SA reported revenue of 1.8B PLN in FY2025 versus 2.2B PLN in FY2021, a compound −4.9%/yr. Reported net income was 61.5M PLN in FY2025, compounding −38.0%/yr from FY2021.
Key figures
Market cap 1.3B PLN (≈ $346M) · P/E ratio 25.0 · P/S ratio 0.85 · EPS (TTM) 2.68 PLN · Dividend yield 4.0% · Net margin 3.4% · Return on equity 3.9% · Return on assets (EBIT) 14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 14% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −27% fair-value upside, at 25%, PCR screens cheaper than that median.
Fair Value models
Bear 64.57 PLNFair Value 83.92 PLNBull 104.91 PLN
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0220 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−8.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.1%
Dividend (yield on the price)4.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12% vs −3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 6%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about −2.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 352 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+25% · Top 25%
Profitability
Return on equity (TTM)4% · Below median
Return on assets3% · Above median
Net margin (TTM)3% · Below median
Operating margin (TTM)1% · Bottom 25%
Growth and dividend
Revenue growth−15% · Bottom 25%
Dividend yield (TTM)4.0% · Top 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PCC Rokita SA Fair Value". https://www.fairvalue-calculator.com/stock/PCR
Frequently asked questions
Is PCC Rokita SA (PCR) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 83.92 PLN versus a price of 67.00 PLN, about +25% upside (undervalued).
What is the fair value of PCR?
Our model-based fair value for PCC Rokita SA is 83.92 PLN (as of Sep 23, 2026), built from audited fundamentals. The current price: 67.00 PLN.
What is the quality score of PCR?
PCC Rokita SA has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PCC Rokita SA (PCR)?
Our model-based price target is the fair value of 83.92 PLN (as of Sep 23, 2026) from 24 valuation models. Cautious scenario 64.57 PLN, optimistic scenario 104.91 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the PCC Rokita SA stock forecast for 2026?
Our models put fair value at 83.92 PLN, about +25% upside versus a price of 67.00 PLN (undervalued). Cautious scenario 64.57 PLN, optimistic scenario 104.91 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of PCC Rokita SA (PCR)?
PCC Rokita SA reported trailing-twelve-month revenue of about 1.7B PLN (latest available figure, as of Sep 23, 2026).
Does PCC Rokita SA pay a dividend?
PCC Rokita SA currently shows a dividend yield of about 3.96% relative to its recent price (as of Sep 23, 2026).
What growth is priced into PCC Rokita SA (PCR)?
For today's price to be fair in a discounted-cash-flow model, PCC Rokita SA would have to grow free cash flow by +0.4 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of PCR use?
Our models discount PCC Rokita SA at 10.9 %: a base by market capitalisation (small), damped by beta 0.60, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PCC Rokita SA that is +0.4 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has PCC Rokita SA (PCR) delivered so far?
Over the past 5 years revenue at PCC Rokita SA grew +4.1 % a year. The price currently implies +0.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PCC Rokita SA (PCR) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into PCC Rokita SA (+0.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PCC Rokita SA (PCR)?
The free-cash-flow yield on the price is 10.86 %: that much free cash flow PCC Rokita SA produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PCC Rokita SA (PCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PCC Rokita SA it is 83.92 PLN per share (as of Sep 23, 2026), against a price of 67.00 PLN. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is PCC Rokita SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PCR trades below its calculated fair value: price 67.00 PLN, fair value 83.92 PLN, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCR?
No. The price is what the market pays today (67.00 PLN); the fair value is what the company's own numbers justify (83.92 PLN). For PCC Rokita SA the two are 16.92 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is PCC Rokita SA worth?
The market values PCC Rokita SA at about 1.3B PLN (market capitalisation, as of Sep 23, 2026). Per share that is 67.00 PLN; our models calculate a fair value of 83.92 PLN per share.
What do the bullish and bearish scenarios say about PCR?
Our models span a range for PCC Rokita SA: cautious scenario 64.57 PLN, base 83.92 PLN, optimistic 104.91 PLN per share (as of Sep 23, 2026, price 67.00 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PCR?
PCC Rokita SA trades at a price-to-earnings ratio of 25.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 83.92 PLN is built from several models across several years. Other multiples: P/B 0.3, P/S 0.2, EV/EBITDA 2.3.
How solid is the balance sheet of PCC Rokita SA (PCR)?
Balance-sheet figures for PCC Rokita SA (as of Sep 23, 2026): return on equity 3.9%, debt of 0.24 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is PCR from its 52-week high?
PCC Rokita SA trades at 67.00 PLN, about 7% below its 52-week high of 71.80 PLN and 14% above the low of 58.65 PLN (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 83.92 PLN is for.
Which stocks are comparable to PCC Rokita SA?
From the same area (Basic Materials) we also value BASF SE, Saudi Basic Industries Corporation, Ningxia Baofeng Energy Group, Dow Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PCC Rokita SA stock attractive at the current price?
The data as of Sep 23, 2026: price 67.00 PLN, calculated fair value 83.92 PLN (+25%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PCR calculated?
We run PCC Rokita SA through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 83.92 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. PCC Rokita SA currently trades 25 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PCC Rokita SA (PCR)?
The closing price on Sep 24, 2026 was 67.00 PLN. Our model-based fair value is 83.92 PLN, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PCC Rokita SA right now?
Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of PCC Rokita SA (PCR) come from?
Earnings per share at PCC Rokita SA grew +19.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share +9.2 %, EBIT margin +8.8 %, tax rate −1.0 %, residual (interest, one-offs) +1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of PCC Rokita SA
How large is the market capitalisation of PCC Rokita SA (PCR)?
The market capitalisation of PCC Rokita SA is 1.3B PLN (≈ $346M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PCC Rokita SA (PCR)?
The price-to-sales ratio of PCC Rokita SA is 0.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PCC Rokita SA (PCR)?
Earnings per share at PCC Rokita SA are 2.68 PLN (price ÷ EPS = P/E 25.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of PCC Rokita SA (PCR)?
The dividend yield of PCC Rokita SA is 4.0% (payout 98.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of PCC Rokita SA (PCR)?
The net margin of PCC Rokita SA is 3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PCC Rokita SA (PCR)?
The return on equity (ROE) of PCC Rokita SA is 3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PCC Rokita SA (PCR)?
On an EBIT basis the return on assets of PCC Rokita SA is 14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PCC Rokita SA (PCR)?
The operating margin of PCC Rokita SA is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PCC Rokita SA (PCR)?
Revenue at PCC Rokita SA is growing −15.0% versus a year earlier (3y avg −16.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PCC Rokita SA (PCR)?
Earnings per share at PCC Rokita SA are growing −80.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PCC Rokita SA (PCR) carry?
The net debt of PCC Rokita SA is 322M PLN (fiscal year 2025, ≈ 2.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PCC Rokita SA in the live analysis
One click puts PCC Rokita SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
